Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

NF-κB as an integrator of diverse signaling pathways

NF-κB as an integrator of diverse signaling pathways NF-κB is a pleiotropic transcription factor implicated in the regulation of diverse biological phenomena, including apoptosis, cell survival, cell growth, cell division, innate immunity, cellular differentiation, and the cellular responses to stress, hypoxia, stretch and ischemia. In the heart, NF-κB has been shown to be activated in atherosclerosis, myocarditis, in association with angina, during transplant rejection, after ischemia/ reperfusion, in congestive heart failure, dilated cardiomyopathy, after ischemic and pharmacological preconditioning, heat shock, burn trauma, and in hypertrophy of isolated cardiomyocytes. Regulation of NF-κB is complicated; in addition to being activated by canonical cytokine-mediated pathways, NF-κB is activated by many of the signal transduction cascades associated with the development of cardiac hypertrophy and response to oxidative stress. Many of these signaling cascades activate NF-κB by activating the lκB kinase (IKK) complex a major component of the canonical pathway. These signaling interactions occur largely via signaling crosstalk involving the mitogen-activated protein kinase/extracellular signaling crosstalk involving the mitogen-activated protein kinase/extracellular signal-regulated kinases (MEKKs) that are components of mitogen activated protein kinase (MAPK) signaling pathways. Additionally, there are other signaling factors that act more directly to activate NF-κB via IκB or by direct phosphorylation of NF-κB subunits. Finally, there are combinatorial interactions at the level of the promoter between NF-κB, its, coativators, and other transcription factors, several of which are activated by MAPK and cytokine signaling pathways. Thus, in addition to being a major mediator of cytokine effects in the heart, NF-κB is positioned as a signaling integrator. As such, NF-κB functions as a key regulator of cardiac gene expression programs downstream of multiple signal transduction cascades in a variety of physiological and pathophysiological states. We show that genetic blockade of NF-κB reduces infarct size in the murine heart after ischemia/reperfusion (I/R), implicating NF-κB as a major determinant of cell death after I/R. These results support the concept that NF-κB may be an important therapeutic target for specific cardiovascular diseases. Furthermore, undertanding the complex signal transduction and gene regulation networks associated with NF-κB functionality will allow us to identify the discrete sets of NF-κB-dependent genes that affect specific pathophysiological phenomena. These genes may be even better therapeutic targets, allowing us to block the injurious effects while preserving the potentially beneficial effects of adaptive signaling in the heart. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Toxicology Springer Journals

NF-κB as an integrator of diverse signaling pathways

Download PDF
25 pages

Loading next page...
 
/lp/springer-journals/nf-b-as-an-integrator-of-diverse-signaling-pathways-4D10FBtAbk

References (287)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Humana Press Inc.
Subject
Biomedicine; Pharmacology/Toxicology; Cardiology
ISSN
1530-7905
eISSN
1559-0259
DOI
10.1385/CT:3:3:229
Publisher site
See Article on Publisher Site

Abstract

NF-κB is a pleiotropic transcription factor implicated in the regulation of diverse biological phenomena, including apoptosis, cell survival, cell growth, cell division, innate immunity, cellular differentiation, and the cellular responses to stress, hypoxia, stretch and ischemia. In the heart, NF-κB has been shown to be activated in atherosclerosis, myocarditis, in association with angina, during transplant rejection, after ischemia/ reperfusion, in congestive heart failure, dilated cardiomyopathy, after ischemic and pharmacological preconditioning, heat shock, burn trauma, and in hypertrophy of isolated cardiomyocytes. Regulation of NF-κB is complicated; in addition to being activated by canonical cytokine-mediated pathways, NF-κB is activated by many of the signal transduction cascades associated with the development of cardiac hypertrophy and response to oxidative stress. Many of these signaling cascades activate NF-κB by activating the lκB kinase (IKK) complex a major component of the canonical pathway. These signaling interactions occur largely via signaling crosstalk involving the mitogen-activated protein kinase/extracellular signaling crosstalk involving the mitogen-activated protein kinase/extracellular signal-regulated kinases (MEKKs) that are components of mitogen activated protein kinase (MAPK) signaling pathways. Additionally, there are other signaling factors that act more directly to activate NF-κB via IκB or by direct phosphorylation of NF-κB subunits. Finally, there are combinatorial interactions at the level of the promoter between NF-κB, its, coativators, and other transcription factors, several of which are activated by MAPK and cytokine signaling pathways. Thus, in addition to being a major mediator of cytokine effects in the heart, NF-κB is positioned as a signaling integrator. As such, NF-κB functions as a key regulator of cardiac gene expression programs downstream of multiple signal transduction cascades in a variety of physiological and pathophysiological states. We show that genetic blockade of NF-κB reduces infarct size in the murine heart after ischemia/reperfusion (I/R), implicating NF-κB as a major determinant of cell death after I/R. These results support the concept that NF-κB may be an important therapeutic target for specific cardiovascular diseases. Furthermore, undertanding the complex signal transduction and gene regulation networks associated with NF-κB functionality will allow us to identify the discrete sets of NF-κB-dependent genes that affect specific pathophysiological phenomena. These genes may be even better therapeutic targets, allowing us to block the injurious effects while preserving the potentially beneficial effects of adaptive signaling in the heart.

Journal

Cardiovascular Toxicology – Springer Journals

Published: Apr 25, 2007

There are no references for this article.